Sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma

ISRCTN	ISRCTN75033520
DOI	https://doi.org/10.1186/ISRCTN75033520
EudraCT/CTIS number	2008-008794-55
ClinicalTrials.gov number	NCT01551459
Secondary identifying numbers	8440

Submission date: 29/10/2010
Registration date: 29/10/2010
Last edited: 26/10/2022

Recruitment status: Stopped
Overall study status: Stopped
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-possible-new-treatment-for-eye-cancer-uveal-melanoma-suave

Contact information

Ms Sarah Jones
Scientific

University of Liverpool Cancer Research Centre
200 London Road
Liverpool
L3 9TA
United Kingdom

Email	jones85@liverpool.ac.uk

Study information

Study design	Multicentre randomised interventional treatment trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details to request a patient information sheet
Scientific title	A randomised Phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma
Study acronym	SUAVE
Study objectives	There is currently no effective systemic therapy for metastatic uveal melanoma. Eligible patients will be randomised to one of two first line interventions: Dacarbazine or Sunitinib. Dacarbazine will be administered at a dose of 1000 mg/m^2 by IV on day 1, and repeated every 21 days until progression or unacceptable toxicity. 50 mg of sunitinib will be taken orally once a day for 28 days followed by 14 day break, until progression or unacceptable toxicity. At baseline, target lesions will be identified by Chest/Abdo CT scan, (and Liver MRI if necessary). Patients will attend clinic every 3 weeks for medical assessments including collection of Adverse Events. Every 12 weeks from day 1 of study treatment (regardless of delays to clinic visits), patients will undergo medical imaging for tumour measurement (in accordance with Recist v1.1). At identification of first progression of disease, it may be possible for the patient to crossover to the other study treatment (if they reach the cross-over eligibility criteria). For patients who cross over, they will continue with the visit schedule until identification of second progression.
Ethics approval(s)	Sunderland Research Ethics Committee, 18/05/2010, ref: 10/H0904/15
Health condition(s) or problem(s) studied	Topic: National Cancer Research Network; Subtopic: Melanoma; Disease: Melanoma
Intervention	Control Arm (Dacarbazine): Dacarbazine 1000 mg/m^2 to be administered by IV on day 1, and repeated every 21 days until progression or unacceptable toxicity. Experimental Arm (Sunitinib): Sunitinib 50 mg to be taken orally once a day for 28 days followed by 14 day break, until progression or unacceptable toxicity. Study entry: single randomisation only
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Phase II
Drug / device / biological / vaccine name(s)	Sunitinib, dacarbazine
Primary outcome measure	Progression free survival - 12 weekly scans will pick up progression according to RECIST 1.1. Analysis of primary outcome will be performed once all patients have been followed up for at least 3 months (expected to be Jan 2013).
Secondary outcome measures	1. Overall survival will be measured from date of randomisation to the date of death from any cause. Patients still alive at the time of analysis are censored at the date of the most recent follow up. 2. Overall response rate is defined as the proportion of complete (CR) or partial responders (PR) as defined by the RECIST version 1.1 3. AEs recorded following randomisation will be classified according to CTCAE version 4.0 4. Time to progression on first-line treatment (TTP1) compared to time to progression on second-line treatment (TTP2) for patients who receive cross-over therapy 5. Overall response rate on first-line treatment (RR1) compared to overall response rate on second-line treatment (RR2) for patients who receive cross-over therapy Initial analysis by Data Monitoring Committee is planned for April 2011. Interim analysis for futility will be conducted after 50% of the events have been observed.
Overall study start date	04/10/2010
Completion date	08/11/2012
Reason abandoned (if study stopped)	Objectives no longer viable

Eligibility

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	Both
Target number of participants	Planned sample size: 124; UK sample size: 124
Key inclusion criteria	1. Patients with histologically or cytologically confirmed unresectable, metastatic uveal melanoma (histology must be available from a metastatic site) 2. Patients with disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent 3. No prior systemic therapy for advanced disease, including regional delivery of drug therapy (prior surgery or radiofrequency ablation is acceptable) 4. Patients who have received prior radiotherapy are eligible, however, measurable lesions must not have been previously irradiated 5. Life expectancy greater than 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (for ECOG scale of performance) 7. At least one measurable target lesion, for further evaluation according to the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 8. Aged greater than 18 years, either sex 9. Adequate haematological, renal and liver function as defined below and performed within 14 days of study inclusion: 9.1. Haemoglobin (Hb) greater than 10 g/dl, platelets greater than 100,000 mm3, white cell count (WCC) greater than 3.0 x 10^9/L, absolute neutrophil count (ANC) greater than 1.5 x 10^9/L 9.2. Bilirubin less than 1.5 x ULN, Alkaline phosphatase less than 5 x ULN, transaminases less than 5 x ULN 9.3. Creatinine less than 1.5 x ULN 10. Able to provide written informed consent 11. Females of child-bearing potential who have a negative pregnancy test prior to study entry and be using adequate contraception, which they agree to continue for 12 months after the study treatment
Key exclusion criteria	1. Conjunctival melanoma 2. Received any previous systemic therapy for uveal melanoma 3. Known leptomeningeal or brain metastases 4. Patients with a history of prior malignant disease (only if they have had more than 3 years free of disease or have had adequately treated non-melanomatous skin cancer or in situ carcinoma of the cervix) 5. Had treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days respectively, prior to study treatment administration 6. Therapeutic anticoagulation for treatment of DVT/PE. Concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin [Coumadin®] up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). 7. Unstable systemic diseases including uncontrolled hypertension (greater than 150/100 mmHg despite optimal medical therapy) or active uncontrolled infections 8. Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischaemic attack, or pulmonary embolism 9. Clinically significant abnormal cardiac function with abnormal 12-lead electrocardiogram (ECG). Ongoing cardiac dysrhythmias of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade more than or equal to grade 2, poorly controlled atrial fibrillation of any grade, or prolongation of the QTc interval to greater than 450 msec for males or greater than 470 msec for females. 10. Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial 11. Any medical or psychiatric condition which would influence the ability to provide informed consent 12. Pregnant or lactating women 13. Lack of informed consent 14. Any previous investigational agent within the last 12 weeks
Date of first enrolment	04/10/2010
Date of final enrolment	08/11/2012

Locations

Countries of recruitment

England
United Kingdom

Study participating centre

University of Liverpool Cancer Research Centre

Liverpool
L3 9TA
United Kingdom

Sponsor information

Clatterbridge Centre for Oncology NHS Foundation Trust (UK)
Hospital/treatment centre

Clatterbridge Hospital
Clatterbridge Road
Wirral
CH63 4JY
England
United Kingdom

Website	http://www.ccotrust.nhs.uk/
"ROR"	https://ror.org/05gcq4j10

Funders

Funder type

Charity

Cancer Research UK (CRUK) (UK) - Clinical Trials Advisory and Awards Committee (CTAAC) grant (ref: CRUK/09/017)
Private sector organisation / Other non-profit organizations

Alternative name(s): CR_UK, Cancer Research UK - London, CRUK
Location: United Kingdom

Pfizer UK
Private sector organisation / For-profit companies (industry)

Alternative name(s): Pfizer Ltd, Pfizer Limited
Location: United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan	Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results			26/10/2022	No	Yes
HRA research summary			28/06/2023	No	No

Editorial Notes

25/10/2022: Cancer Research UK plain English results link added.
06/09/2019: ClinicalTrials.gov number added.
15/11/2017: The trial was stopped.